Proactive Investors - Run By Investors For Investors

Short-seller Andrew Left’s Citron Research doubles down on Namaste Technologies, calls it a 'fraud'

Citron Research published a seven-page report that it claims proves the cannabis company is a fraud
Andrew Left
Andrew Left (pictured) and Namaste CEO Sean Dollinger have sparred before

Short-seller Andrew Left’s Citron Research is doubling down on claims that cannabis e-commerce platform Namaste Technologies Inc (CVE:N, OTCQB:NXTTF) is a fraud.

In a research report, Citron said it had never seen such a blatant fraud being perpetrated and referred to Namaste’s CEO Sean Dollinger as “a walking securities violation.”

READ: Namaste Technologies CEO Sean Dollinger fires back after Andrew Left calls the stock a 'joke'

The report suggested that if Vancouver-based Namaste was a US company, its shares would be halted, and its CEO would face charges.

Nasdaq listing

Last month, Namaste confirmed its plans to uplist to the Nasdaq, citing its jump in sales and increase in share price.

The company reported revenue of $1.65 million for the month of August, 50% higher than the year-ago period.

Citron’s no-holds-barred report said the uplisting claim was fake and used for the sole purpose of luring investors into buying the stock, going on to say that the exchange would “laugh Dollinger out of the room given his seedy background and the company’s opaque finances.”

Namaste’s share price as of Thursday afternoon was $1.70, below the Nasdaq listing requirement of $4 per share, but has reached a 52-week high of $3.47.

Divesting its US assets

In November 2017, Namaste said that it reached a $400,000 agreement with ESC Hughes Holdings Limited to sell its wholly-owned US subsidiary, Dollinger Enterprises US Inc.

The US asset operated two vaporizer websites that had yet to generate a profit.

The company stated that the uncertain climate of the US cannabis market had led to the decision to divest its US assets and focus on the legal cannabis markets.

The report includes a document that appears to show that Namaste executive David Hughes bought Dollinger Enterprises, not a European group as the company had stated.

“By selling our US arm, not only will we be selling it at fair market value, which will give our company positive cash flow for the next twelve months, but the removal of the division will allow us to become profitable by the summer of 2018,” said Dollinger on the November 2017 call.

The report highlights Namaste’s losses and accuses the company of paying money to undisclosed parties, pointing to what it calls “$2.6 million in inexplicable consulting fees.”


The report points to Turning Point Brands Inc’s (NYSE:TPB) recent acquisition of Vapor Group, a company with $48 million in revenue and $5 million in EBITDA, in $24 million deal.

Citron claims that based on this transaction, even if Namaste was a legitimate company with break-even revenue, it would only be worth $0.26 per share.


Left and Dollinger have sparred before following Citron Research’s tweet about Namaste in September.

“Tell [Left] he can come and hang out with me on the weekend, travel around the world," Dollinger told Proactive Investors in an exclusive phone interview last month. "Tell him it’s a formal invite from me. Have him videotape everything we’re doing on site, we’ll prove to him that he’s the joke.”

Citron Research stated it expects to release an additional report on Namaste.

Shares of Namaste fell more than 5% to $1.71 in Thursday afternoon trading.

Cannabis companies CV Sciences Inc (OTCQB:CVSI), Cronos Group Inc (NASDAQ:CRON) and Tilray Inc (NASDAQ:TLRY) have all been targeted by the short-seller.

Namaste Technologies declined to comment on the story at this time.

--Updated to include recent share price and additional information


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use